Insider Trading Alert - TDC, MJN And JAZZ Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 15, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $750.00 to $8,750,000.00.

Highlighted Stocks Traded by Insiders:

Teradata (TDC) - FREE Research Report

Cooper Nancy E, who is Director at Teradata, sold 468 shares at $44.50 on Sept. 15, 2014. Following this transaction, the Director owned 22,919 shares meaning that the stake was reduced by 2% with the 468-share transaction.

The shares most recently traded at $44.88, up $0.38, or 0.85% since the insider transaction. Historical insider transactions for Teradata go as follows:

  • 4-Week # shares bought: 2,680
  • 12-Week # shares bought: 2,680
  • 24-Week # shares bought: 2,680

The average volume for Teradata has been 1.9 million shares per day over the past 30 days. Teradata has a market cap of $7.0 billion and is part of the technology sector and computer hardware industry. Shares are down 0.99% year-to-date as of the close of trading on Monday.

Teradata Corporation provides analytic data platforms, marketing and analytic applications, and related consulting services in the United States and internationally. The company has a P/E ratio of 20.0. Currently, there are 3 analysts who rate Teradata a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TDC - FREE

TheStreet Quant Ratings rates Teradata as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Teradata Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mead Johnson Nutrition (MJN) - FREE Research Report

Golsby Stephen W, who is Director at Mead Johnson Nutrition, sold 10,000 shares at $96.43 on Sept. 15, 2014. Following this transaction, the Director owned 45,458 shares meaning that the stake was reduced by 18.03% with the 10,000-share transaction.

The shares most recently traded at $96.75, up $0.32, or 0.34% since the insider transaction. Historical insider transactions for Mead Johnson Nutrition go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 45,864
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 97,926

The average volume for Mead Johnson Nutrition has been 1.3 million shares per day over the past 30 days. Mead Johnson Nutrition has a market cap of $19.5 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 15.35% year-to-date as of the close of trading on Monday.

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children's nutrition, and other nutritional products. The stock currently has a dividend yield of 1.55%. The company has a P/E ratio of 29.7. Currently, there are 6 analysts who rate Mead Johnson Nutrition a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MJN - FREE

TheStreet Quant Ratings rates Mead Johnson Nutrition as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Mead Johnson Nutrition Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Tobias Jeffrey K, who is EVP, Research & Dev and CMO at Jazz Pharmaceuticals, sold 1,000 shares at $171.22 on Sept. 15, 2014. Following this transaction, the EVP, Research & Dev and CMO owned 41,538 shares meaning that the stake was reduced by 2.35% with the 1,000-share transaction.

Mulligan Seamus, who is Director at Jazz Pharmaceuticals, sold 50,000 shares at $175.00 on Sept. 15, 2014. Following this transaction, the Director owned 1.4 million shares meaning that the stake was reduced by 3.55% with the 50,000-share transaction.

The shares most recently traded at $158.54, down $16.46, or 10.38% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 6,185
  • 12-Week # shares sold: 78,449
  • 24-Week # shares sold: 129,843

The average volume for Jazz Pharmaceuticals has been 948,100 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $10.2 billion and is part of the health care sector and drugs industry. Shares are up 26.7% year-to-date as of the close of trading on Monday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 131.3. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet